TY - JOUR
T1 - Fibrous matrices facilitate pleurocidin killing of wound associated bacterial pathogens
AU - Ramos, Celia
AU - Lorenz, Kairi
AU - Hind, Charlotte K.
AU - Meos, Andres
AU - Laidmäe, Ivo
AU - Tenson, Tanel
AU - Sutton, John
AU - Mason, James
AU - Kogermann, Karin
N1 - Funding Information:
This study is part of the national funding projects no PRG1507 (K.K.) (Estonian Ministry of Education and Research and Estonian Research Council). Mobility funding received from Erasmus + and Archimedes Foundation (Dora Plus and Kristjan Jaak Scholarships) to C.R. has been essential for the international collaboration. Prof K. Kirsimäe, MSc J. Aruväli are thanked for SEM measurements, Dr S. Kasvandik for mass spectroscopy measurements. Graphical abstract created with BioRender.com. Notes. The authors declare no competing financial interest.
Publisher Copyright:
© 2023
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Conventional wound infection treatments neither actively promote wound healing nor address the growing problem of antibacterial resistance. Antimicrobial peptides (AMPs) are natural defense molecules, released from host cells, which may be rapidly bactericidal, modulate host-immune responses, and/or act as endogenous mediators for wound healing. However, their routine clinical use has hitherto been hindered due to their instability in the wound environment. Here we describe an electrospun carrier system for topical application of pleurocidin, demonstrating sufficient AMP release from matrices to kill wound-associated pathogens including Acinetobacter baumannii and Pseudomonas aeruginosa. Pleurocidin can be incorporated into polyvinyl alcohol (PVA) fiber matrices, using coaxial electrospinning, without major drug loss with a peptide content of 0.7% w/w predicted sufficient to kill most wound associated species. Pleurocidin retains its activity on release from the electrospun fiber matrix and completely inhibits growth of two strains of A. baumannii (AYE; ATCC 17978) and other ESKAPE pathogens. Inhibition of P. aeruginosa strains (PAO1; NCTC 13437) is, however, matrix weight per volume dependent, with only larger/thicker matrices maintaining complete inhibition. The resulting estimation of pleurocidin release from the matrix reveals high efficiency, facilitating a greater AMP potency. Wound matrices are often applied in parallel or sequentially with the use of standard wound care with biocides, therefore the presence and effect of biocides on pleurocidin potency was tested. It was revealed that combinations displayed additive or modestly synergistic effects depending on the biocide and pathogens which should be considered during the therapy. Taken together, we show that electrospun, pleurocidin-loaded wound matrices have potential to be investigated for wound infection treatment.
AB - Conventional wound infection treatments neither actively promote wound healing nor address the growing problem of antibacterial resistance. Antimicrobial peptides (AMPs) are natural defense molecules, released from host cells, which may be rapidly bactericidal, modulate host-immune responses, and/or act as endogenous mediators for wound healing. However, their routine clinical use has hitherto been hindered due to their instability in the wound environment. Here we describe an electrospun carrier system for topical application of pleurocidin, demonstrating sufficient AMP release from matrices to kill wound-associated pathogens including Acinetobacter baumannii and Pseudomonas aeruginosa. Pleurocidin can be incorporated into polyvinyl alcohol (PVA) fiber matrices, using coaxial electrospinning, without major drug loss with a peptide content of 0.7% w/w predicted sufficient to kill most wound associated species. Pleurocidin retains its activity on release from the electrospun fiber matrix and completely inhibits growth of two strains of A. baumannii (AYE; ATCC 17978) and other ESKAPE pathogens. Inhibition of P. aeruginosa strains (PAO1; NCTC 13437) is, however, matrix weight per volume dependent, with only larger/thicker matrices maintaining complete inhibition. The resulting estimation of pleurocidin release from the matrix reveals high efficiency, facilitating a greater AMP potency. Wound matrices are often applied in parallel or sequentially with the use of standard wound care with biocides, therefore the presence and effect of biocides on pleurocidin potency was tested. It was revealed that combinations displayed additive or modestly synergistic effects depending on the biocide and pathogens which should be considered during the therapy. Taken together, we show that electrospun, pleurocidin-loaded wound matrices have potential to be investigated for wound infection treatment.
UR - http://www.scopus.com/inward/record.url?scp=85178378814&partnerID=8YFLogxK
U2 - 10.1016/j.ejps.2023.106648
DO - 10.1016/j.ejps.2023.106648
M3 - Article
SN - 0928-0987
VL - 192
JO - EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
JF - EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
M1 - 106648
ER -